drugset
drugset / Trial / NCT05238337

A Phase 1 Study of the Absorption, Metabolism, and Excretion of [14C] PBI-200

NCT05238337 ↗

Phase 1 Completed 6 enrolled Pyramid Biosciences
NaSingle-groupOpen-labelTreatment

Summary

This is a Phase 1, open-label non-randomized, single dose study in healthy male subjects.

Timeline

Start
2022-02-24
Primary completion
2022-03-24
Completion
2022-03-24

Drugs

EvaluationDrugModalityDoseRoute
Subject PALTIMATRECTINIB Small molecule — Oral

Indications

No indication recorded.